{"ast":null,"code":"import React,{useState}from'react';import{motion}from'framer-motion';import{FileText,Download,Print,Share2,Eye,EyeOff,Maximize2,Minimize2,Search,BookOpen,AlertTriangle,CheckCircle,Info}from'lucide-react';import ReactMarkdown from'react-markdown';import{jsx as _jsx,jsxs as _jsxs}from\"react/jsx-runtime\";const MedicalReportViewer=_ref=>{let{reportData,workflowId}=_ref;const[isFullscreen,setIsFullscreen]=useState(false);const[showAnnotations,setShowAnnotations]=useState(true);const[searchTerm,setSearchTerm]=useState('');const[activeSection,setActiveSection]=useState('summary');const reportSections=[{id:'summary',title:'Executive Summary',icon:FileText},{id:'genomics',title:'Genomics Analysis',icon:BookOpen},{id:'clinical',title:'Clinical Significance',icon:AlertTriangle},{id:'recommendations',title:'Recommendations',icon:CheckCircle},{id:'references',title:'References',icon:Info}];const mockReport={patientInfo:{id:workflowId,analysisDate:new Date().toLocaleDateString(),reportType:'Comprehensive Genomics Analysis'},summary:\"\\n# Executive Summary\\n\\nThis comprehensive genomics analysis has identified several clinically significant genetic variants that have important implications for cancer risk assessment and treatment planning.\\n\\n## Key Findings\\n- **High-risk pathogenic variants identified**: 2 variants in BRCA1 and TP53 genes\\n- **Cancer susceptibility**: Significantly elevated risk for hereditary breast and ovarian cancer\\n- **Treatment implications**: PARP inhibitor therapy likely to be highly effective\\n- **Family implications**: Cascade genetic testing recommended for first-degree relatives\\n\\n## Risk Assessment\\nBased on the identified genetic variants, this individual has a **HIGH** risk profile for hereditary cancer syndromes, particularly:\\n- Hereditary Breast and Ovarian Cancer (HBOC) syndrome\\n- Li-Fraumeni syndrome (partial features)\\n\\n## Immediate Actions Required\\n1. Genetic counseling consultation within 2 weeks\\n2. Enhanced cancer screening protocol implementation\\n3. Discussion of risk-reducing surgical options\\n4. Family cascade testing coordination\\n    \",genomics:\"\\n# Genomics Analysis Results\\n\\n## Variant Summary\\nThe analysis identified **29 total variants** across the analyzed genes, with **3 variants of clinical significance**.\\n\\n### Pathogenic Variants\\n\\n#### BRCA1 c.5266dupC (p.Gln1756ProfsTer74)\\n- **Classification**: Pathogenic (Class 5)\\n- **Frequency**: Rare (<0.01% in population)\\n- **Clinical Significance**: Well-established pathogenic variant associated with high cancer risk\\n- **Functional Impact**: Frameshift mutation leading to premature protein truncation\\n- **Cancer Risk**: \\n  - Breast cancer: 72% lifetime risk\\n  - Ovarian cancer: 44% lifetime risk\\n\\n#### TP53 c.524G>A (p.Arg175His)\\n- **Classification**: Likely Pathogenic (Class 4)\\n- **Frequency**: Rare (<0.001% in population)\\n- **Clinical Significance**: Hotspot mutation in DNA-binding domain\\n- **Functional Impact**: Impaired DNA binding and transcriptional activity\\n- **Cancer Risk**: Associated with Li-Fraumeni spectrum cancers\\n\\n### Variants of Uncertain Significance (VUS)\\n\\n#### BRCA1 c.181T>G (p.Cys61Gly)\\n- **Classification**: VUS (Class 3)\\n- **Frequency**: Very rare\\n- **Clinical Significance**: Insufficient evidence for pathogenicity\\n- **Recommendation**: Periodic reclassification as evidence emerges\\n    \",clinical:\"\\n# Clinical Significance and Implications\\n\\n## Cancer Risk Assessment\\n\\n### Hereditary Breast and Ovarian Cancer (HBOC)\\nThe identified BRCA1 pathogenic variant confers significantly elevated cancer risks:\\n\\n**Breast Cancer Risk**\\n- Lifetime risk: ~72% (vs. 12% general population)\\n- Early onset typical (before age 50)\\n- Higher grade, triple-negative subtype common\\n\\n**Ovarian Cancer Risk**\\n- Lifetime risk: ~44% (vs. 1.3% general population)\\n- Typically high-grade serous carcinoma\\n- Often diagnosed at advanced stage\\n\\n### Li-Fraumeni Syndrome Features\\nThe TP53 variant may contribute to:\\n- Early-onset cancers\\n- Multiple primary cancers\\n- Diverse cancer spectrum (sarcomas, brain tumors, adrenocortical carcinoma)\\n\\n## Treatment Implications\\n\\n### Therapeutic Opportunities\\n1. **PARP Inhibitor Sensitivity**\\n   - Olaparib, talazoparib, rucaparib likely highly effective\\n   - Both treatment and prevention applications\\n   \\n2. **Platinum Sensitivity**\\n   - Enhanced response to platinum-based chemotherapy\\n   - Important for treatment planning\\n\\n3. **Immunotherapy Considerations**\\n   - Potential enhanced response to checkpoint inhibitors\\n   - Tumor mutational burden implications\\n\\n### Surgical Considerations\\n- Risk-reducing bilateral mastectomy (90% risk reduction)\\n- Risk-reducing bilateral salpingo-oophorectomy (85-90% ovarian cancer risk reduction)\\n- Timing considerations based on family planning\\n    \",recommendations:\"\\n# Clinical Recommendations\\n\\n## Immediate Actions (Within 2 weeks)\\n\\n### 1. Genetic Counseling Referral\\n- **Urgency**: High priority\\n- **Purpose**: Risk assessment, family planning, surgical options discussion\\n- **Provider**: Board-certified genetic counselor or medical geneticist\\n\\n### 2. Enhanced Screening Protocol\\n**Breast Cancer Screening**\\n- Annual breast MRI starting age 25 (or 10 years before earliest family diagnosis)\\n- Annual mammography starting age 30\\n- Clinical breast examination every 6 months\\n- Monthly breast self-examination\\n\\n**Ovarian Cancer Screening**\\n- Transvaginal ultrasound and CA-125 every 6 months starting age 30\\n- Consider risk-reducing surgery by age 35-40 or after childbearing complete\\n\\n## Medium-term Actions (Within 3 months)\\n\\n### 3. Multidisciplinary Team Consultation\\n- High-risk breast clinic referral\\n- Gynecologic oncology consultation\\n- Plastic surgery consultation (if considering risk-reducing surgery)\\n\\n### 4. Family Cascade Testing\\n- First-degree relatives (parents, siblings, children over 18)\\n- Genetic counseling for family members\\n- Coordinate testing through genetics clinic\\n\\n## Long-term Management\\n\\n### 5. Lifestyle Modifications\\n- Maintain healthy weight\\n- Regular exercise\\n- Limit alcohol consumption\\n- Avoid hormone replacement therapy\\n- Consider chemoprevention options\\n\\n### 6. Reproductive Planning\\n- Preimplantation genetic diagnosis (PGD) options\\n- Fertility preservation before risk-reducing surgery\\n- Genetic counseling for reproductive decisions\\n\\n## Follow-up Schedule\\n- Genetics clinic: 6 months\\n- High-risk breast clinic: Every 6 months\\n- Gynecologic oncology: Annually\\n- Primary care: Continue routine care with awareness of genetic status\\n    \",references:\"\\n# References and Supporting Evidence\\n\\n## Clinical Guidelines\\n1. NCCN Guidelines Version 1.2024, Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic\\n2. ACMG Standards and Guidelines for the Interpretation of Sequence Variants\\n3. ASCO Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility\\n\\n## Key Publications\\n1. Kuchenbaecker KB, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317(23):2402-2416.\\n\\n2. Robson M, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017;377(6):523-533.\\n\\n3. Bougeard G, et al. Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers. J Clin Oncol. 2015;33(21):2345-52.\\n\\n## Database References\\n- ClinVar: Variant classifications and clinical significance\\n- HGMD: Human Gene Mutation Database\\n- LOVD: Leiden Open Variation Database\\n- BIC: Breast Cancer Information Core\\n\\n## Laboratory Information\\n- **Testing Laboratory**: Biomerkin Genomics Laboratory\\n- **Test Method**: Next-generation sequencing with confirmatory Sanger sequencing\\n- **Coverage**: >99% for all analyzed regions\\n- **Sensitivity**: >99% for single nucleotide variants and small indels\\n    \"};const highlightSearchTerm=text=>{if(!searchTerm)return text;const regex=new RegExp(\"(\".concat(searchTerm,\")\"),'gi');return text.replace(regex,'<mark class=\"bg-yellow-200\">$1</mark>');};const downloadReport=format=>{// Implementation would depend on backend API\nconsole.log(\"Downloading report in \".concat(format,\" format\"));};const printReport=()=>{window.print();};const shareReport=()=>{if(navigator.share){navigator.share({title:'Medical Genomics Report',text:'Comprehensive genomics analysis report',url:window.location.href});}};return/*#__PURE__*/_jsxs(\"div\",{className:\"bg-white \".concat(isFullscreen?'fixed inset-0 z-50':'rounded-lg border border-gray-200'),children:[/*#__PURE__*/_jsxs(\"div\",{className:\"flex items-center justify-between p-6 border-b border-gray-200\",children:[/*#__PURE__*/_jsxs(\"div\",{children:[/*#__PURE__*/_jsx(\"h2\",{className:\"text-2xl font-bold text-gray-900\",children:\"Medical Genomics Report\"}),/*#__PURE__*/_jsxs(\"div\",{className:\"flex items-center space-x-4 mt-1 text-sm text-gray-600\",children:[/*#__PURE__*/_jsxs(\"span\",{children:[\"Patient ID: \",mockReport.patientInfo.id]}),/*#__PURE__*/_jsx(\"span\",{children:\"\\u2022\"}),/*#__PURE__*/_jsxs(\"span\",{children:[\"Date: \",mockReport.patientInfo.analysisDate]}),/*#__PURE__*/_jsx(\"span\",{children:\"\\u2022\"}),/*#__PURE__*/_jsx(\"span\",{children:mockReport.patientInfo.reportType})]})]}),/*#__PURE__*/_jsxs(\"div\",{className:\"flex items-center space-x-2\",children:[/*#__PURE__*/_jsxs(\"div\",{className:\"relative\",children:[/*#__PURE__*/_jsx(Search,{className:\"absolute left-3 top-1/2 transform -translate-y-1/2 h-4 w-4 text-gray-400\"}),/*#__PURE__*/_jsx(\"input\",{type:\"text\",placeholder:\"Search report...\",value:searchTerm,onChange:e=>setSearchTerm(e.target.value),className:\"pl-10 pr-4 py-2 border border-gray-300 rounded-lg text-sm focus:ring-2 focus:ring-blue-500 focus:border-transparent\"})]}),/*#__PURE__*/_jsx(\"button\",{onClick:()=>setShowAnnotations(!showAnnotations),className:\"p-2 text-gray-600 hover:text-gray-900 hover:bg-gray-100 rounded-lg transition-colors\",title:showAnnotations?'Hide annotations':'Show annotations',children:showAnnotations?/*#__PURE__*/_jsx(EyeOff,{className:\"h-4 w-4\"}):/*#__PURE__*/_jsx(Eye,{className:\"h-4 w-4\"})}),/*#__PURE__*/_jsx(\"button\",{onClick:()=>setIsFullscreen(!isFullscreen),className:\"p-2 text-gray-600 hover:text-gray-900 hover:bg-gray-100 rounded-lg transition-colors\",title:isFullscreen?'Exit fullscreen':'Enter fullscreen',children:isFullscreen?/*#__PURE__*/_jsx(Minimize2,{className:\"h-4 w-4\"}):/*#__PURE__*/_jsx(Maximize2,{className:\"h-4 w-4\"})}),/*#__PURE__*/_jsxs(\"div\",{className:\"flex items-center space-x-1 border-l border-gray-300 pl-2\",children:[/*#__PURE__*/_jsx(\"button\",{onClick:printReport,className:\"p-2 text-gray-600 hover:text-gray-900 hover:bg-gray-100 rounded-lg transition-colors\",title:\"Print report\",children:/*#__PURE__*/_jsx(Print,{className:\"h-4 w-4\"})}),/*#__PURE__*/_jsx(\"button\",{onClick:shareReport,className:\"p-2 text-gray-600 hover:text-gray-900 hover:bg-gray-100 rounded-lg transition-colors\",title:\"Share report\",children:/*#__PURE__*/_jsx(Share2,{className:\"h-4 w-4\"})}),/*#__PURE__*/_jsxs(\"div\",{className:\"relative group\",children:[/*#__PURE__*/_jsx(\"button\",{className:\"p-2 text-gray-600 hover:text-gray-900 hover:bg-gray-100 rounded-lg transition-colors\",children:/*#__PURE__*/_jsx(Download,{className:\"h-4 w-4\"})}),/*#__PURE__*/_jsxs(\"div\",{className:\"absolute right-0 mt-2 w-48 bg-white rounded-lg shadow-lg border border-gray-200 opacity-0 invisible group-hover:opacity-100 group-hover:visible transition-all duration-200 z-10\",children:[/*#__PURE__*/_jsx(\"button\",{onClick:()=>downloadReport('pdf'),className:\"w-full text-left px-4 py-2 hover:bg-gray-50 rounded-t-lg\",children:\"Download PDF\"}),/*#__PURE__*/_jsx(\"button\",{onClick:()=>downloadReport('docx'),className:\"w-full text-left px-4 py-2 hover:bg-gray-50\",children:\"Download Word\"}),/*#__PURE__*/_jsx(\"button\",{onClick:()=>downloadReport('html'),className:\"w-full text-left px-4 py-2 hover:bg-gray-50 rounded-b-lg\",children:\"Download HTML\"})]})]})]})]})]}),/*#__PURE__*/_jsxs(\"div\",{className:\"flex h-full\",children:[/*#__PURE__*/_jsx(\"div\",{className:\"w-64 border-r border-gray-200 bg-gray-50\",children:/*#__PURE__*/_jsx(\"nav\",{className:\"p-4 space-y-2\",children:reportSections.map(section=>{const Icon=section.icon;return/*#__PURE__*/_jsxs(\"button\",{onClick:()=>setActiveSection(section.id),className:\"w-full flex items-center space-x-3 px-3 py-2 rounded-lg text-left transition-colors \".concat(activeSection===section.id?'bg-blue-100 text-blue-700 font-medium':'text-gray-700 hover:bg-gray-100'),children:[/*#__PURE__*/_jsx(Icon,{className:\"h-4 w-4\"}),/*#__PURE__*/_jsx(\"span\",{className:\"text-sm\",children:section.title})]},section.id);})})}),/*#__PURE__*/_jsx(\"div\",{className:\"flex-1 overflow-y-auto\",children:/*#__PURE__*/_jsx(\"div\",{className:\"p-8 max-w-4xl mx-auto\",children:/*#__PURE__*/_jsx(motion.div,{initial:{opacity:0,y:20},animate:{opacity:1,y:0},transition:{duration:0.3},className:\"prose prose-lg max-w-none\",children:/*#__PURE__*/_jsx(\"div\",{className:\"medical-report-content\",dangerouslySetInnerHTML:{__html:highlightSearchTerm(mockReport[activeSection]||'')}})},activeSection)})})]}),/*#__PURE__*/_jsx(\"div\",{className:\"border-t border-gray-200 p-4 bg-gray-50 text-center text-sm text-gray-600\",children:/*#__PURE__*/_jsxs(\"p\",{children:[\"This report was generated by Biomerkin AI Agent System \\u2022 For questions, contact your healthcare provider \\u2022 Report ID: \",workflowId]})}),/*#__PURE__*/_jsx(\"style\",{jsx:true,children:\"\\n        .medical-report-content {\\n          font-family: 'Georgia', serif;\\n          line-height: 1.6;\\n        }\\n        \\n        .medical-report-content h1 {\\n          color: #1f2937;\\n          border-bottom: 2px solid #3b82f6;\\n          padding-bottom: 0.5rem;\\n          margin-bottom: 1.5rem;\\n        }\\n        \\n        .medical-report-content h2 {\\n          color: #374151;\\n          margin-top: 2rem;\\n          margin-bottom: 1rem;\\n        }\\n        \\n        .medical-report-content h3 {\\n          color: #4b5563;\\n          margin-top: 1.5rem;\\n          margin-bottom: 0.75rem;\\n        }\\n        \\n        .medical-report-content strong {\\n          color: #1f2937;\\n        }\\n        \\n        .medical-report-content ul {\\n          margin-left: 1.5rem;\\n        }\\n        \\n        .medical-report-content li {\\n          margin-bottom: 0.5rem;\\n        }\\n        \\n        @media print {\\n          .medical-report-content {\\n            font-size: 12pt;\\n            line-height: 1.4;\\n          }\\n        }\\n      \"})]});};export default MedicalReportViewer;","map":{"version":3,"names":["React","useState","motion","FileText","Download","Print","Share2","Eye","EyeOff","Maximize2","Minimize2","Search","BookOpen","AlertTriangle","CheckCircle","Info","ReactMarkdown","jsx","_jsx","jsxs","_jsxs","MedicalReportViewer","_ref","reportData","workflowId","isFullscreen","setIsFullscreen","showAnnotations","setShowAnnotations","searchTerm","setSearchTerm","activeSection","setActiveSection","reportSections","id","title","icon","mockReport","patientInfo","analysisDate","Date","toLocaleDateString","reportType","summary","genomics","clinical","recommendations","references","highlightSearchTerm","text","regex","RegExp","concat","replace","downloadReport","format","console","log","printReport","window","print","shareReport","navigator","share","url","location","href","className","children","type","placeholder","value","onChange","e","target","onClick","map","section","Icon","div","initial","opacity","y","animate","transition","duration","dangerouslySetInnerHTML","__html"],"sources":["C:/Users/Sumit/Desktop/Biomerkin/frontend/src/components/MedicalReportViewer.js"],"sourcesContent":["import React, { useState } from 'react';\r\nimport { motion } from 'framer-motion';\r\nimport { \r\n  FileText, \r\n  Download, \r\n  Print, \r\n  Share2, \r\n  Eye,\r\n  EyeOff,\r\n  Maximize2,\r\n  Minimize2,\r\n  Search,\r\n  BookOpen,\r\n  AlertTriangle,\r\n  CheckCircle,\r\n  Info\r\n} from 'lucide-react';\r\nimport ReactMarkdown from 'react-markdown';\r\n\r\nconst MedicalReportViewer = ({ reportData, workflowId }) => {\r\n  const [isFullscreen, setIsFullscreen] = useState(false);\r\n  const [showAnnotations, setShowAnnotations] = useState(true);\r\n  const [searchTerm, setSearchTerm] = useState('');\r\n  const [activeSection, setActiveSection] = useState('summary');\r\n\r\n  const reportSections = [\r\n    { id: 'summary', title: 'Executive Summary', icon: FileText },\r\n    { id: 'genomics', title: 'Genomics Analysis', icon: BookOpen },\r\n    { id: 'clinical', title: 'Clinical Significance', icon: AlertTriangle },\r\n    { id: 'recommendations', title: 'Recommendations', icon: CheckCircle },\r\n    { id: 'references', title: 'References', icon: Info }\r\n  ];\r\n\r\n  const mockReport = {\r\n    patientInfo: {\r\n      id: workflowId,\r\n      analysisDate: new Date().toLocaleDateString(),\r\n      reportType: 'Comprehensive Genomics Analysis'\r\n    },\r\n    summary: `\r\n# Executive Summary\r\n\r\nThis comprehensive genomics analysis has identified several clinically significant genetic variants that have important implications for cancer risk assessment and treatment planning.\r\n\r\n## Key Findings\r\n- **High-risk pathogenic variants identified**: 2 variants in BRCA1 and TP53 genes\r\n- **Cancer susceptibility**: Significantly elevated risk for hereditary breast and ovarian cancer\r\n- **Treatment implications**: PARP inhibitor therapy likely to be highly effective\r\n- **Family implications**: Cascade genetic testing recommended for first-degree relatives\r\n\r\n## Risk Assessment\r\nBased on the identified genetic variants, this individual has a **HIGH** risk profile for hereditary cancer syndromes, particularly:\r\n- Hereditary Breast and Ovarian Cancer (HBOC) syndrome\r\n- Li-Fraumeni syndrome (partial features)\r\n\r\n## Immediate Actions Required\r\n1. Genetic counseling consultation within 2 weeks\r\n2. Enhanced cancer screening protocol implementation\r\n3. Discussion of risk-reducing surgical options\r\n4. Family cascade testing coordination\r\n    `,\r\n    genomics: `\r\n# Genomics Analysis Results\r\n\r\n## Variant Summary\r\nThe analysis identified **29 total variants** across the analyzed genes, with **3 variants of clinical significance**.\r\n\r\n### Pathogenic Variants\r\n\r\n#### BRCA1 c.5266dupC (p.Gln1756ProfsTer74)\r\n- **Classification**: Pathogenic (Class 5)\r\n- **Frequency**: Rare (<0.01% in population)\r\n- **Clinical Significance**: Well-established pathogenic variant associated with high cancer risk\r\n- **Functional Impact**: Frameshift mutation leading to premature protein truncation\r\n- **Cancer Risk**: \r\n  - Breast cancer: 72% lifetime risk\r\n  - Ovarian cancer: 44% lifetime risk\r\n\r\n#### TP53 c.524G>A (p.Arg175His)\r\n- **Classification**: Likely Pathogenic (Class 4)\r\n- **Frequency**: Rare (<0.001% in population)\r\n- **Clinical Significance**: Hotspot mutation in DNA-binding domain\r\n- **Functional Impact**: Impaired DNA binding and transcriptional activity\r\n- **Cancer Risk**: Associated with Li-Fraumeni spectrum cancers\r\n\r\n### Variants of Uncertain Significance (VUS)\r\n\r\n#### BRCA1 c.181T>G (p.Cys61Gly)\r\n- **Classification**: VUS (Class 3)\r\n- **Frequency**: Very rare\r\n- **Clinical Significance**: Insufficient evidence for pathogenicity\r\n- **Recommendation**: Periodic reclassification as evidence emerges\r\n    `,\r\n    clinical: `\r\n# Clinical Significance and Implications\r\n\r\n## Cancer Risk Assessment\r\n\r\n### Hereditary Breast and Ovarian Cancer (HBOC)\r\nThe identified BRCA1 pathogenic variant confers significantly elevated cancer risks:\r\n\r\n**Breast Cancer Risk**\r\n- Lifetime risk: ~72% (vs. 12% general population)\r\n- Early onset typical (before age 50)\r\n- Higher grade, triple-negative subtype common\r\n\r\n**Ovarian Cancer Risk**\r\n- Lifetime risk: ~44% (vs. 1.3% general population)\r\n- Typically high-grade serous carcinoma\r\n- Often diagnosed at advanced stage\r\n\r\n### Li-Fraumeni Syndrome Features\r\nThe TP53 variant may contribute to:\r\n- Early-onset cancers\r\n- Multiple primary cancers\r\n- Diverse cancer spectrum (sarcomas, brain tumors, adrenocortical carcinoma)\r\n\r\n## Treatment Implications\r\n\r\n### Therapeutic Opportunities\r\n1. **PARP Inhibitor Sensitivity**\r\n   - Olaparib, talazoparib, rucaparib likely highly effective\r\n   - Both treatment and prevention applications\r\n   \r\n2. **Platinum Sensitivity**\r\n   - Enhanced response to platinum-based chemotherapy\r\n   - Important for treatment planning\r\n\r\n3. **Immunotherapy Considerations**\r\n   - Potential enhanced response to checkpoint inhibitors\r\n   - Tumor mutational burden implications\r\n\r\n### Surgical Considerations\r\n- Risk-reducing bilateral mastectomy (90% risk reduction)\r\n- Risk-reducing bilateral salpingo-oophorectomy (85-90% ovarian cancer risk reduction)\r\n- Timing considerations based on family planning\r\n    `,\r\n    recommendations: `\r\n# Clinical Recommendations\r\n\r\n## Immediate Actions (Within 2 weeks)\r\n\r\n### 1. Genetic Counseling Referral\r\n- **Urgency**: High priority\r\n- **Purpose**: Risk assessment, family planning, surgical options discussion\r\n- **Provider**: Board-certified genetic counselor or medical geneticist\r\n\r\n### 2. Enhanced Screening Protocol\r\n**Breast Cancer Screening**\r\n- Annual breast MRI starting age 25 (or 10 years before earliest family diagnosis)\r\n- Annual mammography starting age 30\r\n- Clinical breast examination every 6 months\r\n- Monthly breast self-examination\r\n\r\n**Ovarian Cancer Screening**\r\n- Transvaginal ultrasound and CA-125 every 6 months starting age 30\r\n- Consider risk-reducing surgery by age 35-40 or after childbearing complete\r\n\r\n## Medium-term Actions (Within 3 months)\r\n\r\n### 3. Multidisciplinary Team Consultation\r\n- High-risk breast clinic referral\r\n- Gynecologic oncology consultation\r\n- Plastic surgery consultation (if considering risk-reducing surgery)\r\n\r\n### 4. Family Cascade Testing\r\n- First-degree relatives (parents, siblings, children over 18)\r\n- Genetic counseling for family members\r\n- Coordinate testing through genetics clinic\r\n\r\n## Long-term Management\r\n\r\n### 5. Lifestyle Modifications\r\n- Maintain healthy weight\r\n- Regular exercise\r\n- Limit alcohol consumption\r\n- Avoid hormone replacement therapy\r\n- Consider chemoprevention options\r\n\r\n### 6. Reproductive Planning\r\n- Preimplantation genetic diagnosis (PGD) options\r\n- Fertility preservation before risk-reducing surgery\r\n- Genetic counseling for reproductive decisions\r\n\r\n## Follow-up Schedule\r\n- Genetics clinic: 6 months\r\n- High-risk breast clinic: Every 6 months\r\n- Gynecologic oncology: Annually\r\n- Primary care: Continue routine care with awareness of genetic status\r\n    `,\r\n    references: `\r\n# References and Supporting Evidence\r\n\r\n## Clinical Guidelines\r\n1. NCCN Guidelines Version 1.2024, Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic\r\n2. ACMG Standards and Guidelines for the Interpretation of Sequence Variants\r\n3. ASCO Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility\r\n\r\n## Key Publications\r\n1. Kuchenbaecker KB, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317(23):2402-2416.\r\n\r\n2. Robson M, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017;377(6):523-533.\r\n\r\n3. Bougeard G, et al. Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers. J Clin Oncol. 2015;33(21):2345-52.\r\n\r\n## Database References\r\n- ClinVar: Variant classifications and clinical significance\r\n- HGMD: Human Gene Mutation Database\r\n- LOVD: Leiden Open Variation Database\r\n- BIC: Breast Cancer Information Core\r\n\r\n## Laboratory Information\r\n- **Testing Laboratory**: Biomerkin Genomics Laboratory\r\n- **Test Method**: Next-generation sequencing with confirmatory Sanger sequencing\r\n- **Coverage**: >99% for all analyzed regions\r\n- **Sensitivity**: >99% for single nucleotide variants and small indels\r\n    `\r\n  };\r\n\r\n  const highlightSearchTerm = (text) => {\r\n    if (!searchTerm) return text;\r\n    const regex = new RegExp(`(${searchTerm})`, 'gi');\r\n    return text.replace(regex, '<mark class=\"bg-yellow-200\">$1</mark>');\r\n  };\r\n\r\n  const downloadReport = (format) => {\r\n    // Implementation would depend on backend API\r\n    console.log(`Downloading report in ${format} format`);\r\n  };\r\n\r\n  const printReport = () => {\r\n    window.print();\r\n  };\r\n\r\n  const shareReport = () => {\r\n    if (navigator.share) {\r\n      navigator.share({\r\n        title: 'Medical Genomics Report',\r\n        text: 'Comprehensive genomics analysis report',\r\n        url: window.location.href\r\n      });\r\n    }\r\n  };\r\n\r\n  return (\r\n    <div className={`bg-white ${isFullscreen ? 'fixed inset-0 z-50' : 'rounded-lg border border-gray-200'}`}>\r\n      {/* Report Header */}\r\n      <div className=\"flex items-center justify-between p-6 border-b border-gray-200\">\r\n        <div>\r\n          <h2 className=\"text-2xl font-bold text-gray-900\">Medical Genomics Report</h2>\r\n          <div className=\"flex items-center space-x-4 mt-1 text-sm text-gray-600\">\r\n            <span>Patient ID: {mockReport.patientInfo.id}</span>\r\n            <span>•</span>\r\n            <span>Date: {mockReport.patientInfo.analysisDate}</span>\r\n            <span>•</span>\r\n            <span>{mockReport.patientInfo.reportType}</span>\r\n          </div>\r\n        </div>\r\n        \r\n        <div className=\"flex items-center space-x-2\">\r\n          <div className=\"relative\">\r\n            <Search className=\"absolute left-3 top-1/2 transform -translate-y-1/2 h-4 w-4 text-gray-400\" />\r\n            <input\r\n              type=\"text\"\r\n              placeholder=\"Search report...\"\r\n              value={searchTerm}\r\n              onChange={(e) => setSearchTerm(e.target.value)}\r\n              className=\"pl-10 pr-4 py-2 border border-gray-300 rounded-lg text-sm focus:ring-2 focus:ring-blue-500 focus:border-transparent\"\r\n            />\r\n          </div>\r\n          \r\n          <button\r\n            onClick={() => setShowAnnotations(!showAnnotations)}\r\n            className=\"p-2 text-gray-600 hover:text-gray-900 hover:bg-gray-100 rounded-lg transition-colors\"\r\n            title={showAnnotations ? 'Hide annotations' : 'Show annotations'}\r\n          >\r\n            {showAnnotations ? <EyeOff className=\"h-4 w-4\" /> : <Eye className=\"h-4 w-4\" />}\r\n          </button>\r\n          \r\n          <button\r\n            onClick={() => setIsFullscreen(!isFullscreen)}\r\n            className=\"p-2 text-gray-600 hover:text-gray-900 hover:bg-gray-100 rounded-lg transition-colors\"\r\n            title={isFullscreen ? 'Exit fullscreen' : 'Enter fullscreen'}\r\n          >\r\n            {isFullscreen ? <Minimize2 className=\"h-4 w-4\" /> : <Maximize2 className=\"h-4 w-4\" />}\r\n          </button>\r\n          \r\n          <div className=\"flex items-center space-x-1 border-l border-gray-300 pl-2\">\r\n            <button\r\n              onClick={printReport}\r\n              className=\"p-2 text-gray-600 hover:text-gray-900 hover:bg-gray-100 rounded-lg transition-colors\"\r\n              title=\"Print report\"\r\n            >\r\n              <Print className=\"h-4 w-4\" />\r\n            </button>\r\n            \r\n            <button\r\n              onClick={shareReport}\r\n              className=\"p-2 text-gray-600 hover:text-gray-900 hover:bg-gray-100 rounded-lg transition-colors\"\r\n              title=\"Share report\"\r\n            >\r\n              <Share2 className=\"h-4 w-4\" />\r\n            </button>\r\n            \r\n            <div className=\"relative group\">\r\n              <button className=\"p-2 text-gray-600 hover:text-gray-900 hover:bg-gray-100 rounded-lg transition-colors\">\r\n                <Download className=\"h-4 w-4\" />\r\n              </button>\r\n              \r\n              <div className=\"absolute right-0 mt-2 w-48 bg-white rounded-lg shadow-lg border border-gray-200 opacity-0 invisible group-hover:opacity-100 group-hover:visible transition-all duration-200 z-10\">\r\n                <button\r\n                  onClick={() => downloadReport('pdf')}\r\n                  className=\"w-full text-left px-4 py-2 hover:bg-gray-50 rounded-t-lg\"\r\n                >\r\n                  Download PDF\r\n                </button>\r\n                <button\r\n                  onClick={() => downloadReport('docx')}\r\n                  className=\"w-full text-left px-4 py-2 hover:bg-gray-50\"\r\n                >\r\n                  Download Word\r\n                </button>\r\n                <button\r\n                  onClick={() => downloadReport('html')}\r\n                  className=\"w-full text-left px-4 py-2 hover:bg-gray-50 rounded-b-lg\"\r\n                >\r\n                  Download HTML\r\n                </button>\r\n              </div>\r\n            </div>\r\n          </div>\r\n        </div>\r\n      </div>\r\n\r\n      <div className=\"flex h-full\">\r\n        {/* Section Navigation */}\r\n        <div className=\"w-64 border-r border-gray-200 bg-gray-50\">\r\n          <nav className=\"p-4 space-y-2\">\r\n            {reportSections.map((section) => {\r\n              const Icon = section.icon;\r\n              return (\r\n                <button\r\n                  key={section.id}\r\n                  onClick={() => setActiveSection(section.id)}\r\n                  className={`w-full flex items-center space-x-3 px-3 py-2 rounded-lg text-left transition-colors ${\r\n                    activeSection === section.id\r\n                      ? 'bg-blue-100 text-blue-700 font-medium'\r\n                      : 'text-gray-700 hover:bg-gray-100'\r\n                  }`}\r\n                >\r\n                  <Icon className=\"h-4 w-4\" />\r\n                  <span className=\"text-sm\">{section.title}</span>\r\n                </button>\r\n              );\r\n            })}\r\n          </nav>\r\n        </div>\r\n\r\n        {/* Report Content */}\r\n        <div className=\"flex-1 overflow-y-auto\">\r\n          <div className=\"p-8 max-w-4xl mx-auto\">\r\n            <motion.div\r\n              key={activeSection}\r\n              initial={{ opacity: 0, y: 20 }}\r\n              animate={{ opacity: 1, y: 0 }}\r\n              transition={{ duration: 0.3 }}\r\n              className=\"prose prose-lg max-w-none\"\r\n            >\r\n              <div \r\n                className=\"medical-report-content\"\r\n                dangerouslySetInnerHTML={{\r\n                  __html: highlightSearchTerm(mockReport[activeSection] || '')\r\n                }}\r\n              />\r\n            </motion.div>\r\n          </div>\r\n        </div>\r\n      </div>\r\n\r\n      {/* Report Footer */}\r\n      <div className=\"border-t border-gray-200 p-4 bg-gray-50 text-center text-sm text-gray-600\">\r\n        <p>\r\n          This report was generated by Biomerkin AI Agent System • \r\n          For questions, contact your healthcare provider • \r\n          Report ID: {workflowId}\r\n        </p>\r\n      </div>\r\n\r\n      <style jsx>{`\r\n        .medical-report-content {\r\n          font-family: 'Georgia', serif;\r\n          line-height: 1.6;\r\n        }\r\n        \r\n        .medical-report-content h1 {\r\n          color: #1f2937;\r\n          border-bottom: 2px solid #3b82f6;\r\n          padding-bottom: 0.5rem;\r\n          margin-bottom: 1.5rem;\r\n        }\r\n        \r\n        .medical-report-content h2 {\r\n          color: #374151;\r\n          margin-top: 2rem;\r\n          margin-bottom: 1rem;\r\n        }\r\n        \r\n        .medical-report-content h3 {\r\n          color: #4b5563;\r\n          margin-top: 1.5rem;\r\n          margin-bottom: 0.75rem;\r\n        }\r\n        \r\n        .medical-report-content strong {\r\n          color: #1f2937;\r\n        }\r\n        \r\n        .medical-report-content ul {\r\n          margin-left: 1.5rem;\r\n        }\r\n        \r\n        .medical-report-content li {\r\n          margin-bottom: 0.5rem;\r\n        }\r\n        \r\n        @media print {\r\n          .medical-report-content {\r\n            font-size: 12pt;\r\n            line-height: 1.4;\r\n          }\r\n        }\r\n      `}</style>\r\n    </div>\r\n  );\r\n};\r\n\r\nexport default MedicalReportViewer;"],"mappings":"AAAA,MAAO,CAAAA,KAAK,EAAIC,QAAQ,KAAQ,OAAO,CACvC,OAASC,MAAM,KAAQ,eAAe,CACtC,OACEC,QAAQ,CACRC,QAAQ,CACRC,KAAK,CACLC,MAAM,CACNC,GAAG,CACHC,MAAM,CACNC,SAAS,CACTC,SAAS,CACTC,MAAM,CACNC,QAAQ,CACRC,aAAa,CACbC,WAAW,CACXC,IAAI,KACC,cAAc,CACrB,MAAO,CAAAC,aAAa,KAAM,gBAAgB,CAAC,OAAAC,GAAA,IAAAC,IAAA,CAAAC,IAAA,IAAAC,KAAA,yBAE3C,KAAM,CAAAC,mBAAmB,CAAGC,IAAA,EAAgC,IAA/B,CAAEC,UAAU,CAAEC,UAAW,CAAC,CAAAF,IAAA,CACrD,KAAM,CAACG,YAAY,CAAEC,eAAe,CAAC,CAAGzB,QAAQ,CAAC,KAAK,CAAC,CACvD,KAAM,CAAC0B,eAAe,CAAEC,kBAAkB,CAAC,CAAG3B,QAAQ,CAAC,IAAI,CAAC,CAC5D,KAAM,CAAC4B,UAAU,CAAEC,aAAa,CAAC,CAAG7B,QAAQ,CAAC,EAAE,CAAC,CAChD,KAAM,CAAC8B,aAAa,CAAEC,gBAAgB,CAAC,CAAG/B,QAAQ,CAAC,SAAS,CAAC,CAE7D,KAAM,CAAAgC,cAAc,CAAG,CACrB,CAAEC,EAAE,CAAE,SAAS,CAAEC,KAAK,CAAE,mBAAmB,CAAEC,IAAI,CAAEjC,QAAS,CAAC,CAC7D,CAAE+B,EAAE,CAAE,UAAU,CAAEC,KAAK,CAAE,mBAAmB,CAAEC,IAAI,CAAExB,QAAS,CAAC,CAC9D,CAAEsB,EAAE,CAAE,UAAU,CAAEC,KAAK,CAAE,uBAAuB,CAAEC,IAAI,CAAEvB,aAAc,CAAC,CACvE,CAAEqB,EAAE,CAAE,iBAAiB,CAAEC,KAAK,CAAE,iBAAiB,CAAEC,IAAI,CAAEtB,WAAY,CAAC,CACtE,CAAEoB,EAAE,CAAE,YAAY,CAAEC,KAAK,CAAE,YAAY,CAAEC,IAAI,CAAErB,IAAK,CAAC,CACtD,CAED,KAAM,CAAAsB,UAAU,CAAG,CACjBC,WAAW,CAAE,CACXJ,EAAE,CAAEV,UAAU,CACde,YAAY,CAAE,GAAI,CAAAC,IAAI,CAAC,CAAC,CAACC,kBAAkB,CAAC,CAAC,CAC7CC,UAAU,CAAE,iCACd,CAAC,CACDC,OAAO,ojCAqBN,CACDC,QAAQ,2uCA+BP,CACDC,QAAQ,y6CA2CP,CACDC,eAAe,ouDAoDd,CACDC,UAAU,+vCA2BZ,CAAC,CAED,KAAM,CAAAC,mBAAmB,CAAIC,IAAI,EAAK,CACpC,GAAI,CAACpB,UAAU,CAAE,MAAO,CAAAoB,IAAI,CAC5B,KAAM,CAAAC,KAAK,CAAG,GAAI,CAAAC,MAAM,KAAAC,MAAA,CAAKvB,UAAU,MAAK,IAAI,CAAC,CACjD,MAAO,CAAAoB,IAAI,CAACI,OAAO,CAACH,KAAK,CAAE,uCAAuC,CAAC,CACrE,CAAC,CAED,KAAM,CAAAI,cAAc,CAAIC,MAAM,EAAK,CACjC;AACAC,OAAO,CAACC,GAAG,0BAAAL,MAAA,CAA0BG,MAAM,WAAS,CAAC,CACvD,CAAC,CAED,KAAM,CAAAG,WAAW,CAAGA,CAAA,GAAM,CACxBC,MAAM,CAACC,KAAK,CAAC,CAAC,CAChB,CAAC,CAED,KAAM,CAAAC,WAAW,CAAGA,CAAA,GAAM,CACxB,GAAIC,SAAS,CAACC,KAAK,CAAE,CACnBD,SAAS,CAACC,KAAK,CAAC,CACd5B,KAAK,CAAE,yBAAyB,CAChCc,IAAI,CAAE,wCAAwC,CAC9Ce,GAAG,CAAEL,MAAM,CAACM,QAAQ,CAACC,IACvB,CAAC,CAAC,CACJ,CACF,CAAC,CAED,mBACE9C,KAAA,QAAK+C,SAAS,aAAAf,MAAA,CAAc3B,YAAY,CAAG,oBAAoB,CAAG,mCAAmC,CAAG,CAAA2C,QAAA,eAEtGhD,KAAA,QAAK+C,SAAS,CAAC,gEAAgE,CAAAC,QAAA,eAC7EhD,KAAA,QAAAgD,QAAA,eACElD,IAAA,OAAIiD,SAAS,CAAC,kCAAkC,CAAAC,QAAA,CAAC,yBAAuB,CAAI,CAAC,cAC7EhD,KAAA,QAAK+C,SAAS,CAAC,wDAAwD,CAAAC,QAAA,eACrEhD,KAAA,SAAAgD,QAAA,EAAM,cAAY,CAAC/B,UAAU,CAACC,WAAW,CAACJ,EAAE,EAAO,CAAC,cACpDhB,IAAA,SAAAkD,QAAA,CAAM,QAAC,CAAM,CAAC,cACdhD,KAAA,SAAAgD,QAAA,EAAM,QAAM,CAAC/B,UAAU,CAACC,WAAW,CAACC,YAAY,EAAO,CAAC,cACxDrB,IAAA,SAAAkD,QAAA,CAAM,QAAC,CAAM,CAAC,cACdlD,IAAA,SAAAkD,QAAA,CAAO/B,UAAU,CAACC,WAAW,CAACI,UAAU,CAAO,CAAC,EAC7C,CAAC,EACH,CAAC,cAENtB,KAAA,QAAK+C,SAAS,CAAC,6BAA6B,CAAAC,QAAA,eAC1ChD,KAAA,QAAK+C,SAAS,CAAC,UAAU,CAAAC,QAAA,eACvBlD,IAAA,CAACP,MAAM,EAACwD,SAAS,CAAC,0EAA0E,CAAE,CAAC,cAC/FjD,IAAA,UACEmD,IAAI,CAAC,MAAM,CACXC,WAAW,CAAC,kBAAkB,CAC9BC,KAAK,CAAE1C,UAAW,CAClB2C,QAAQ,CAAGC,CAAC,EAAK3C,aAAa,CAAC2C,CAAC,CAACC,MAAM,CAACH,KAAK,CAAE,CAC/CJ,SAAS,CAAC,qHAAqH,CAChI,CAAC,EACC,CAAC,cAENjD,IAAA,WACEyD,OAAO,CAAEA,CAAA,GAAM/C,kBAAkB,CAAC,CAACD,eAAe,CAAE,CACpDwC,SAAS,CAAC,sFAAsF,CAChGhC,KAAK,CAAER,eAAe,CAAG,kBAAkB,CAAG,kBAAmB,CAAAyC,QAAA,CAEhEzC,eAAe,cAAGT,IAAA,CAACV,MAAM,EAAC2D,SAAS,CAAC,SAAS,CAAE,CAAC,cAAGjD,IAAA,CAACX,GAAG,EAAC4D,SAAS,CAAC,SAAS,CAAE,CAAC,CACzE,CAAC,cAETjD,IAAA,WACEyD,OAAO,CAAEA,CAAA,GAAMjD,eAAe,CAAC,CAACD,YAAY,CAAE,CAC9C0C,SAAS,CAAC,sFAAsF,CAChGhC,KAAK,CAAEV,YAAY,CAAG,iBAAiB,CAAG,kBAAmB,CAAA2C,QAAA,CAE5D3C,YAAY,cAAGP,IAAA,CAACR,SAAS,EAACyD,SAAS,CAAC,SAAS,CAAE,CAAC,cAAGjD,IAAA,CAACT,SAAS,EAAC0D,SAAS,CAAC,SAAS,CAAE,CAAC,CAC/E,CAAC,cAET/C,KAAA,QAAK+C,SAAS,CAAC,2DAA2D,CAAAC,QAAA,eACxElD,IAAA,WACEyD,OAAO,CAAEjB,WAAY,CACrBS,SAAS,CAAC,sFAAsF,CAChGhC,KAAK,CAAC,cAAc,CAAAiC,QAAA,cAEpBlD,IAAA,CAACb,KAAK,EAAC8D,SAAS,CAAC,SAAS,CAAE,CAAC,CACvB,CAAC,cAETjD,IAAA,WACEyD,OAAO,CAAEd,WAAY,CACrBM,SAAS,CAAC,sFAAsF,CAChGhC,KAAK,CAAC,cAAc,CAAAiC,QAAA,cAEpBlD,IAAA,CAACZ,MAAM,EAAC6D,SAAS,CAAC,SAAS,CAAE,CAAC,CACxB,CAAC,cAET/C,KAAA,QAAK+C,SAAS,CAAC,gBAAgB,CAAAC,QAAA,eAC7BlD,IAAA,WAAQiD,SAAS,CAAC,sFAAsF,CAAAC,QAAA,cACtGlD,IAAA,CAACd,QAAQ,EAAC+D,SAAS,CAAC,SAAS,CAAE,CAAC,CAC1B,CAAC,cAET/C,KAAA,QAAK+C,SAAS,CAAC,kLAAkL,CAAAC,QAAA,eAC/LlD,IAAA,WACEyD,OAAO,CAAEA,CAAA,GAAMrB,cAAc,CAAC,KAAK,CAAE,CACrCa,SAAS,CAAC,0DAA0D,CAAAC,QAAA,CACrE,cAED,CAAQ,CAAC,cACTlD,IAAA,WACEyD,OAAO,CAAEA,CAAA,GAAMrB,cAAc,CAAC,MAAM,CAAE,CACtCa,SAAS,CAAC,6CAA6C,CAAAC,QAAA,CACxD,eAED,CAAQ,CAAC,cACTlD,IAAA,WACEyD,OAAO,CAAEA,CAAA,GAAMrB,cAAc,CAAC,MAAM,CAAE,CACtCa,SAAS,CAAC,0DAA0D,CAAAC,QAAA,CACrE,eAED,CAAQ,CAAC,EACN,CAAC,EACH,CAAC,EACH,CAAC,EACH,CAAC,EACH,CAAC,cAENhD,KAAA,QAAK+C,SAAS,CAAC,aAAa,CAAAC,QAAA,eAE1BlD,IAAA,QAAKiD,SAAS,CAAC,0CAA0C,CAAAC,QAAA,cACvDlD,IAAA,QAAKiD,SAAS,CAAC,eAAe,CAAAC,QAAA,CAC3BnC,cAAc,CAAC2C,GAAG,CAAEC,OAAO,EAAK,CAC/B,KAAM,CAAAC,IAAI,CAAGD,OAAO,CAACzC,IAAI,CACzB,mBACEhB,KAAA,WAEEuD,OAAO,CAAEA,CAAA,GAAM3C,gBAAgB,CAAC6C,OAAO,CAAC3C,EAAE,CAAE,CAC5CiC,SAAS,wFAAAf,MAAA,CACPrB,aAAa,GAAK8C,OAAO,CAAC3C,EAAE,CACxB,uCAAuC,CACvC,iCAAiC,CACpC,CAAAkC,QAAA,eAEHlD,IAAA,CAAC4D,IAAI,EAACX,SAAS,CAAC,SAAS,CAAE,CAAC,cAC5BjD,IAAA,SAAMiD,SAAS,CAAC,SAAS,CAAAC,QAAA,CAAES,OAAO,CAAC1C,KAAK,CAAO,CAAC,GAT3C0C,OAAO,CAAC3C,EAUP,CAAC,CAEb,CAAC,CAAC,CACC,CAAC,CACH,CAAC,cAGNhB,IAAA,QAAKiD,SAAS,CAAC,wBAAwB,CAAAC,QAAA,cACrClD,IAAA,QAAKiD,SAAS,CAAC,uBAAuB,CAAAC,QAAA,cACpClD,IAAA,CAAChB,MAAM,CAAC6E,GAAG,EAETC,OAAO,CAAE,CAAEC,OAAO,CAAE,CAAC,CAAEC,CAAC,CAAE,EAAG,CAAE,CAC/BC,OAAO,CAAE,CAAEF,OAAO,CAAE,CAAC,CAAEC,CAAC,CAAE,CAAE,CAAE,CAC9BE,UAAU,CAAE,CAAEC,QAAQ,CAAE,GAAI,CAAE,CAC9BlB,SAAS,CAAC,2BAA2B,CAAAC,QAAA,cAErClD,IAAA,QACEiD,SAAS,CAAC,wBAAwB,CAClCmB,uBAAuB,CAAE,CACvBC,MAAM,CAAEvC,mBAAmB,CAACX,UAAU,CAACN,aAAa,CAAC,EAAI,EAAE,CAC7D,CAAE,CACH,CAAC,EAXGA,aAYK,CAAC,CACV,CAAC,CACH,CAAC,EACH,CAAC,cAGNb,IAAA,QAAKiD,SAAS,CAAC,2EAA2E,CAAAC,QAAA,cACxFhD,KAAA,MAAAgD,QAAA,EAAG,kIAGU,CAAC5C,UAAU,EACrB,CAAC,CACD,CAAC,cAENN,IAAA,UAAOD,GAAG,MAAAmD,QAAA,kiCA2CD,CAAC,EACP,CAAC,CAEV,CAAC,CAED,cAAe,CAAA/C,mBAAmB","ignoreList":[]},"metadata":{},"sourceType":"module","externalDependencies":[]}